DK3049056T3 - Topisk antisvampesammensætning og fremgangsmåder til behandling - Google Patents

Topisk antisvampesammensætning og fremgangsmåder til behandling Download PDF

Info

Publication number
DK3049056T3
DK3049056T3 DK14781264.8T DK14781264T DK3049056T3 DK 3049056 T3 DK3049056 T3 DK 3049056T3 DK 14781264 T DK14781264 T DK 14781264T DK 3049056 T3 DK3049056 T3 DK 3049056T3
Authority
DK
Denmark
Prior art keywords
treatment
methods
topical anti
fungal composition
fungal
Prior art date
Application number
DK14781264.8T
Other languages
English (en)
Other versions
DK3049056T4 (da
Inventor
John Ridden
Michael Davies
Liam Good
Original Assignee
Blueberry Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49553377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3049056(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Blueberry Therapeutics Ltd filed Critical Blueberry Therapeutics Ltd
Application granted granted Critical
Publication of DK3049056T3 publication Critical patent/DK3049056T3/da
Publication of DK3049056T4 publication Critical patent/DK3049056T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0023—Drug applicators using microneedles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medical Informatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK14781264.8T 2013-09-25 2014-09-25 Topisk antisvampesammensætning og fremgangsmåder til behandling DK3049056T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1317005.5A GB201317005D0 (en) 2013-09-25 2013-09-25 Composition and methods of treatment
GBGB1320723.8A GB201320723D0 (en) 2013-09-25 2013-11-25 Composition and methods of treatment
PCT/GB2014/052911 WO2015044669A1 (en) 2013-09-25 2014-09-25 Antifungal topical composition and methods of treatment

Publications (2)

Publication Number Publication Date
DK3049056T3 true DK3049056T3 (da) 2019-07-29
DK3049056T4 DK3049056T4 (da) 2022-08-01

Family

ID=49553377

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14781264.8T DK3049056T4 (da) 2013-09-25 2014-09-25 Topisk antisvampesammensætning og fremgangsmåder til behandling

Country Status (16)

Country Link
US (2) US11185511B2 (da)
EP (3) EP3049056B2 (da)
JP (2) JP6581569B2 (da)
CN (1) CN105579028B (da)
CY (1) CY1123414T1 (da)
DK (1) DK3049056T4 (da)
ES (2) ES2738662T5 (da)
GB (2) GB201317005D0 (da)
HR (1) HRP20191304T4 (da)
HU (1) HUE044589T2 (da)
LT (1) LT3049056T (da)
PL (1) PL3049056T5 (da)
PT (1) PT3049056T (da)
RS (1) RS59211B2 (da)
SI (1) SI3049056T2 (da)
WO (1) WO2015044669A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201317005D0 (en) * 2013-09-25 2013-11-06 Blueberry Therapeutics Ltd Composition and methods of treatment
US11110071B2 (en) * 2015-06-19 2021-09-07 Global Health Solutions Llc Petrolatum-based PHMB compositions and methods of treatment for onychomycosis
GB201511799D0 (en) 2015-07-06 2015-08-19 Blueberry Therapeutics Ltd Composition and methods of treatment
CA3018629A1 (en) * 2016-03-24 2017-09-28 Locate Therapeutics Limited Scaffolding material, methods and uses
GB201605127D0 (en) 2016-03-25 2016-05-11 Blueberry Therapeutics Ltd Composition and methods of treatment
JP6310977B2 (ja) * 2016-09-07 2018-04-11 株式会社日本総合研究所 爪用シール及びシールシート
WO2018162271A1 (en) 2017-03-05 2018-09-13 Rita Dobmeyer Nanoparticles for the treatment of macular degeneration
GB201710491D0 (en) 2017-06-30 2017-08-16 Blueberry Therapeutics Ltd Composition and methods of treatment
KR102060138B1 (ko) * 2018-05-30 2019-12-27 연세대학교 산학협력단 안구용 마이크로니들 주사의 제조방법
GB201810925D0 (en) * 2018-07-03 2018-08-15 Blueberry Therapeutics Ltd Compositions and methods of treatment
GB201810923D0 (en) * 2018-07-03 2018-08-15 Blueberry Therapeutics Ltd Compositions and method of treatment
CA3127079A1 (en) * 2019-01-16 2020-07-23 Global Health Solutions Llc Petrolatum-based phmb compositions and methods of treatment for onychomycosis
GB201908229D0 (en) * 2019-06-10 2019-07-24 Univ College Cork National Univ Of Ireland Microneedles and methods for the manufacture thereof
CN110898075B (zh) * 2019-12-27 2021-08-03 温海 聚六亚甲基双胍在制备抑制和/或杀灭犬小孢子菌的药物中的应用
CN111067897A (zh) * 2020-01-20 2020-04-28 中山大学 一种抗真菌的组合物及其应用
EP4110305A1 (en) * 2020-02-26 2023-01-04 Biosergen AS Pharmaceutical compositions of a therapeutic polyene macrolide and methods of their use
CN111588689B (zh) * 2020-06-20 2023-08-11 温州医科大学 一种角膜微创可溶性微针贴片及其制备方法与应用
CN112168845A (zh) * 2020-11-13 2021-01-05 郑虹 一种用于治疗手足癣的药物软膏及其制备方法
DE102021118997A1 (de) * 2021-07-22 2023-01-26 Lts Lohmann Therapie-Systeme Ag. Mikronadelarray mit Antiseptika
CN113567217A (zh) * 2021-07-27 2021-10-29 肖波 一种妇科荧光染色液
WO2023154464A1 (en) * 2022-02-11 2023-08-17 Fairleigh Dickinson University Locally administered compositions and methods of use thereof
KR102597564B1 (ko) * 2023-03-03 2023-11-03 장병모 조갑 및 피부 백선의 예방 또는 치료용 약학적 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2761886B1 (fr) * 1997-04-14 2000-05-05 Virbac Sa Compositions contenant au moins un polymere cationique et au moins une molecule active contenue dans au moins un vecteur micro ou nanoparticulaire, et leur utilisation pour le traitement de surfaces vivantes ou inertes
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
NZ542904A (en) * 2003-03-21 2009-04-30 Nexmed Holdings Inc Antifungal nail coat and method of use
US7871649B2 (en) * 2003-07-17 2011-01-18 The Trustees Of Columbia University In The City Of New York Antimicrobial compositions containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof
US20050238672A1 (en) * 2004-04-27 2005-10-27 Nimni Marcel E Antifungal drug delivery
AU2005247328B2 (en) * 2004-05-03 2011-03-10 Shalon Ventures, L.P. Polycationic antimicrobial therapeutic
WO2006138719A2 (en) * 2005-06-17 2006-12-28 Georgia Tech Research Corporation Coated microstructures and method of manufacture thereof
CN101208129B (zh) * 2005-06-27 2011-03-30 3M创新有限公司 微针药筒组件及其施放方法
EP1909868A1 (en) * 2005-07-25 2008-04-16 Nanotechnology Victoria PTY Ltd Microarray device
US20070249546A1 (en) * 2006-04-22 2007-10-25 Sawaya Assad S Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them
EP2054339A4 (en) 2006-08-11 2011-08-03 Panacea Biotec Ltd PARTICULARS FOR ACTIVE INHIBITION, MANUFACTURING METHOD AND COMPOSITIONS THEREOF
EP2073848B1 (en) * 2006-10-05 2013-08-28 The Johns Hopkins University Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles
US20100021530A1 (en) * 2008-07-25 2010-01-28 Innovation Biomedical Devices, Inc. Enhanced trans-keratin drug delivery
CN101724284B (zh) * 2008-10-31 2012-06-27 中国石油化工股份有限公司 一种抗菌热塑性塑料组合物及其制备方法
JP5408592B2 (ja) 2010-03-19 2014-02-05 コスメディ製薬株式会社 マイクロニードルの迅速溶解法
JP2012235899A (ja) 2011-05-12 2012-12-06 Bioserentack Co Ltd 大量の目的物質を皮膚内へデリバリーするためのマイクロニードル・アレイ・チップ
BR112013033239A2 (pt) 2011-06-22 2016-09-06 Vyome Biosciences pró-farmácos de conjugado baseado em atifungicos e antibacterianos
GB201117538D0 (en) 2011-10-11 2011-11-23 Royal Veterinary College The Methods
EP2664327A1 (en) * 2012-05-14 2013-11-20 Almirall S.A. Topical pharmaceutical compositions comprising terbinafide and urea
GB201317005D0 (en) * 2013-09-25 2013-11-06 Blueberry Therapeutics Ltd Composition and methods of treatment

Also Published As

Publication number Publication date
RS59211B1 (sr) 2019-10-31
ES2738662T3 (es) 2020-01-24
US20160206567A1 (en) 2016-07-21
CN105579028B (zh) 2020-03-20
RS59211B2 (sr) 2022-07-29
US20220133640A1 (en) 2022-05-05
EP3854380A1 (en) 2021-07-28
GB201317005D0 (en) 2013-11-06
DK3049056T4 (da) 2022-08-01
EP3501498A1 (en) 2019-06-26
ES2738662T5 (es) 2022-09-21
PL3049056T5 (pl) 2022-09-12
LT3049056T (lt) 2019-08-26
SI3049056T1 (sl) 2019-11-29
EP3501498B1 (en) 2020-11-25
CY1123414T1 (el) 2022-03-24
HRP20191304T1 (hr) 2019-10-18
PL3049056T3 (pl) 2019-10-31
GB201320723D0 (en) 2014-01-08
SI3049056T2 (sl) 2022-08-31
EP3049056A1 (en) 2016-08-03
HRP20191304T4 (hr) 2022-07-22
WO2015044669A1 (en) 2015-04-02
PT3049056T (pt) 2019-07-25
US11185511B2 (en) 2021-11-30
JP2016536271A (ja) 2016-11-24
JP2019218393A (ja) 2019-12-26
EP3049056B1 (en) 2019-04-24
EP3049056B2 (en) 2022-06-01
ES2859518T3 (es) 2021-10-04
HUE044589T2 (hu) 2019-11-28
JP6581569B2 (ja) 2019-09-25
JP7028836B2 (ja) 2022-03-02
CN105579028A (zh) 2016-05-11

Similar Documents

Publication Publication Date Title
DK3049056T3 (da) Topisk antisvampesammensætning og fremgangsmåder til behandling
DK3019200T3 (da) Oligonukleotid-ligand-konjugater og fremgangsmåde til fremstiling deraf
DK3035955T3 (da) Sammensætning og vaccine til behandling af lungekræft
DK3087095T3 (da) FcRn-antagonist og fremgangsmåder til anvendelse
DK3043784T3 (da) Arylethere og anvendelser deraf
DK3080274T3 (da) Fremgangsmåder og sammensætninger til genom-manipulation
DK3009021T3 (da) Handske og fremgangsmåde til fremstilling deraf
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK2961831T3 (da) Sammensætninger og fremgangsmåder til immunterapi
DK3019483T3 (da) Terapeutiske aktive forbindelser og fremgangsmåder til deres anvendelse
DK2900657T3 (da) Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse
DK3086807T3 (da) Antistoffer og fremgangsmåder til anvendelse
DK3082902T3 (da) Kropsbåret injektor og anvendelsesmetode
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
DK3007695T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
DK3063144T3 (da) Antiparasitære og pesticid-isoxazolinforbindelser
DK2962100T3 (da) Tuberkulosebiomarkører og anvendelser deraf
DK2994533T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
DK3030549T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3020408T3 (da) Traditionel kinesisk medicinsammensætning og fremstilling og anvendelse heraf
DK3033081T3 (da) Sammensætninger og fremgangsmåder til behandling af kronisk urticaria
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf
DK3058936T3 (da) Peptidsammensætning og anvendelser deraf
DK3074008T3 (da) Forbindelser, farmaceutisk sammensætning og fremgangsmåder til anvendelse i behandling af inflammation